Double-Blind Randomized Phase 2 Trial Testing Personal Cancer Vaccines in Patients with Advanced Ovarian Cancer.

Area of Science:

• Oncology
• Immunotherapy
• Vaccine Development

Background:

• Dendritic cell vaccines represent a promising avenue for cancer immunotherapy.
• AV-OVA-1 is a personalized vaccine utilizing autologous dendritic cells (DCs) and autologous tumor antigens (ATA) derived from tumor-initiating cells (TICs).

Purpose of the Study:

• To assess the manufacturing feasibility, safety, and efficacy of the AV-OVA-1 vaccine.
• To evaluate AV-OVA-1 in patients with newly diagnosed stage 3 or 4 ovarian cancer.

Main Methods:

• A multicenter, double-blind, randomized phase 2 trial.
• Patients received AV-OVA-1 or autologous monocytes (MC) subcutaneously after chemotherapy and surgery.
• Stratification based on disease persistence and randomization (2:1) to treatment arms.

Main Results:

• High manufacturing success rates for TICs (97.2%), monocyte products (94.0%), and AV-OVA-1 (96.7%).
• Adverse events were similar, mild-to-moderate, and self-limited across both arms.
• AV-OVA-1 treatment led to increased T-cell immune responses, but the study was underpowered for survival analysis.

Conclusions:

• AV-OVA-1 demonstrated reliable manufacturing processes.
• The AV-OVA-1 vaccine was well-tolerated by patients, with no significant safety concerns.
• The vaccine showed potential in eliciting immune responses, warranting further investigation in larger trials.